NRXS NeurAxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock? NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges. | ||
 Is Kodak having a "Kodak moment?" 2 watchlist stocks. KODK and NRXS are worth watching for their growth. | ||
 NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin. | ||
 NeurAxis, Inc. Q2 2026 Earnings Call Summary Moby summary of NeurAxis, Inc.'s Q2 2026 earnings call | ||
Neuraxis Inc (NRXS) (Q2 2026) Earnings Call Highlights: Revenue Surges 116% as Payer Coverage ... Neuraxis Inc (NRXS) reports record Q2 growth with gross margins expanding to 85.9% while strategically investing in VA channel expansion and large payer negotiations. | ||